RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have earned an average rating of “Hold” from the thirteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

Several equities analysts recently weighed in on RAPT shares. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday, November 12th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, UBS Group reduced their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th.

RAPT Therapeutics Stock Down 3.3 %

Shares of RAPT opened at $1.04 on Friday. The company has a 50 day moving average of $1.86 and a two-hundred day moving average of $2.80. RAPT Therapeutics has a twelve month low of $1.00 and a twelve month high of $27.35. The company has a market cap of $36.18 million, a price-to-earnings ratio of -0.37 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, sell-side analysts expect that RAPT Therapeutics will post -2.8 EPS for the current year.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds have recently made changes to their positions in RAPT. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics in the third quarter worth approximately $36,000. Barclays PLC boosted its stake in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in RAPT Therapeutics during the 1st quarter worth $97,000. XTX Topco Ltd purchased a new stake in shares of RAPT Therapeutics during the second quarter worth $108,000. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.